Inhibrx Biosciences CEO Mark Lappe acquires $984,588 of common shares

Bitget2026/09/28 21:48

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Inhibrx Biosciences CEO Mark P. Lappe reported open-market purchases of 9,? shares via the Lappe Family Trust.
Purchases were disclosed at weighted-average prices of USD 98.8659, USD 99.5988, USD 98.8803, USD 101.702.
Trust holdings rose to 740,548 shares following the transactions.
Separate indirect holdings listed at 165,000 shares in the Lappe Descendants' Trust.
Additional indirect stake reported at 54,865 shares in The Mark Paul Lappe Roth IRA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001366074-26-000004), on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Inhibrx Biosciences CEO Mark Lappe acquires $984,588 of common shares

You may also like

Crypto prices